Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Depreciation and Depletion (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Depreciation and Depletion for 13 consecutive years, with $100000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation and Depletion changed 0.0% to $100000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $200000.0, a 60.0% decrease, with the full-year FY2025 number at $200000.0, down 77.78% from a year prior.
  • Depreciation and Depletion was $100000.0 for Q4 2025 at Aytu Biopharma, roughly flat from $100000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $500000.0 in Q2 2021 to a low of $100000.0 in Q2 2024.
  • A 5-year average of $276470.6 and a median of $300000.0 in 2022 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: surged 1112.12% in 2021, then crashed 66.67% in 2024.
  • Aytu Biopharma's Depreciation and Depletion stood at $400000.0 in 2021, then changed by 0.0% to $400000.0 in 2022, then dropped by 25.0% to $300000.0 in 2023, then plummeted by 66.67% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Depreciation and Depletion are $100000.0 (Q4 2025), $100000.0 (Q3 2025), and $100000.0 (Q4 2024).